4 years on, the Cassava Sciences tale ended Monday precisely as many knew it could — with the corporate’s experimental drug for Alzheimer’s illness, simufilam, proving to be not anything greater than a placebo in a big medical trial.
The destructive result is devastating for the just about 2,000 contributors on this find out about and a 2nd find out about additionally close down Monday. Scientific trials in Alzheimer’s fail all too regularly, however simufilam used to be constructed on falsified analysis and deceptive efficacy claims. The drug will have to by no means have complex this a ways.
It’s heartbreaking to imagine the time — years, in lots of instances — that individuals with Alzheimer’s misplaced through collaborating in Cassava’s Section 3 trials.
STAT+ Unique Tale
Have already got an account? Log in
This text is unique to STAT+ subscribers
Release this newsletter — plus in-depth research, newsletters, top class occasions, and information indicators.
Have already got an account? Log in
Person plans
Crew plans
View All Plans
To learn the remainder of this tale subscribe to STAT+.
Subscribe
